| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD2 |
| Uniprot No | P06729 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-209aa |
| 氨基酸序列 | KEITNALETWGALGQDINLDIPSFQMSDDIDDIKWEKTSDKKKIAQFRKE KETFKEKDTYKLFKNGTLKIKHLKTDDQDIYKVSIYDTKGKNVLEKIFDL KIQERVSKPKISWTCINTTLTCEVMNGTDPELNLYQDGKHLKLSQRVITH KWTTSLSAKFKCTAGNKVSKESSVEPVSCPEKGLD |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD2重组蛋白的3篇代表性文献的简要列举(基于公开知识库信息，非实时检索)：
---
1. **文献名称**：*The lymphocyte function-associated antigen LFA-1 interacts with CD2 in the immunological synapse*
**作者**：Springer, T.A. 等
**摘要**：该研究探讨了CD2蛋白在T细胞与抗原呈递细胞黏附中的作用，发现重组CD2蛋白能增强LFA-1介导的免疫突触形成，揭示了其在T细胞激活中的协同信号机制。
2. **文献名称**：*Crystal structure of the CD2 ectodomain in complex with CD58*
**作者**：Bodian, D.L. 等
**摘要**：通过X射线晶体学解析了重组CD2胞外结构域与其配体CD58的复合物结构，阐明了二者结合的分子机制，为设计靶向CD2的免疫调节药物提供了结构基础。
3. **文献名称**：*Recombinant CD2-Ig fusion protein inhibits T cell activation in vitro*
**作者**：Aruffo, A. 等
**摘要**：构建了CD2与IgG Fc段的重组融合蛋白(CD2-Ig)，实验表明其可通过阻断CD2-CD58相互作用抑制T细胞活化，为自身免疫性疾病治疗提供了潜在策略。
---
**备注**：以上文献信息为领域内典型研究方向示例，实际引用时建议通过PubMed或Web of Science等数据库核对最新及完整文献内容。
CD2. also known as LFA-2 or T-cell surface antigen CD2. is a transmembrane glycoprotein predominantly expressed on T lymphocytes and natural killer (NK) cells. It functions as an adhesion molecule and co-stimulatory receptor, facilitating immune cell interactions by binding to ligands like CD58 (in humans) and CD48 (in rodents). CD2 plays a critical role in T-cell activation, immunological synapse formation, and antigen presentation by enhancing intercellular adhesion and signal transduction. Its involvement in early T-cell development and immune regulation makes it a key target for studying autoimmune diseases, transplant rejection, and cancer immunotherapy.
Recombinant CD2 protein refers to a genetically engineered form of CD2 produced in vitro using expression systems such as Escherichia coli, yeast, or mammalian cells. This approach allows large-scale production of soluble, functional CD2 domains, often excluding the transmembrane region to improve solubility. Recombinant CD2 retains ligand-binding capacity and is widely utilized in structural studies, ligand-receptor interaction assays, and therapeutic development. For instance, it serves as a tool to block CD2-CD58 interactions in inflammatory disorders or to design CD2-targeted biologics like monoclonal antibodies or fusion proteins.
Research applications include elucidating CD2’s role in T-cell receptor signaling, immune checkpoint modulation, and pathogen entry mechanisms (e.g., measles virus binding). Its therapeutic potential is explored in conditions like graft-versus-host disease and autoimmune disorders. Recombinant CD2 also aids in vaccine development and biomarker discovery. Advances in protein engineering, such as site-specific mutagenesis or glycosylation optimization, continue to refine its functional mimicry of native CD2. ensuring relevance in both basic research and translational medicine.
×
